William Kvasnicka
Medical · Chicago, ILNPI 1801225024
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,165 of the $19,242 with a category attached, or 68.4%. 34 manufacturers reported payments, led by Gilead at 41.4% of the total. Among medical clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 564 payments — averaging $34.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$8K
- Viiv Healthcare Company$5K
- Janssen Scientific Affairs, LLC$1K
- Merck$866
- Janssen Products, LP$850
- Johnson & Johnson$571
- plus $3K from 28 others
What the payments were for
- Consulting fees$5,68030%
- Speaking & faculty fees$2932%
- Travel & lodging$260%
- Food & beverage$13,16568%
- Education$780%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 173 | $7,968 |
| Viiv Healthcare Company | 208 | $5,192 |
| Janssen Scientific Affairs, LLC | 1 | $1,160 |
| Merck | 36 | $866 |
| Janssen Products, LP | 3 | $850 |
| Johnson & Johnson(2 entities) | 32 | $571 |
| AbbVie | 14 | $352 |
| Novo Nordisk | 11 | $334 |
| Mckesson Medical-surgical, Inc. | 1 | $275 |
| Theratechnologies Inc. | 10 | $228 |
| Antares Pharma, Inc. | 12 | $201 |
| Pfizer | 7 | $171 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $160 |
| Napo Pharmaceuticals Inc | 6 | $132 |
| Dynavax Technologies Corporation | 8 | $93 |
| EMD Serono, Inc. | 4 | $83 |
| GSK | 4 | $74 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| Amgen | 3 | $57 |
| Indivior Inc. | 2 | $44 |
| Exact Sciences | 2 | $41 |
| Oxford Immunotec USA Inc | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Braeburn Inc. | 2 | $30 |
| Seqirus USA Inc | 1 | $29 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $22 |
| Alkermes, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Halozyme Inc | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,242 in reported general payments places this provider in the 95th percentile of 449 medical providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 99 | $409,216 |
| DescovyEmtricitabine/Tenofov Alafenam | 37 | $83,384 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $39,451 |
| OzempicSemaglutide | 13 | $15,265 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,117 |
| ValacyclovirValacyclovir Hcl | 32 | $752 |
| Rosuvastatin Calcium | 29 | $481 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $422 |
| Atorvastatin Calcium | 25 | $295 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $208 |
| Fluticasone Propionate | 11 | $201 |
| Finasteride | 11 | $197 |
| Spironolactone | 15 | $169 |
| Metoprolol Succinate | 13 | $160 |
| Zolpidem Tartrate | 18 | $114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $7,968 | $492,601136 claims |
| Viiv Healthcare CompanyDovato | $5,192 | $39,45113 claims |
| Novo NordiskOzempic | $334 | $15,26513 claims |
| GSKTrelegy Ellipta | $74 | $7,11711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 449 medical providers in Illinois.
Other medical in Chicago
- Andrea TurekChicago$145K
- Jennifer GarsonChicago$32K
- Brittany WolfeChicago$12K
- Eric KingChicago$9K
- Neema ManappuramChicago$8K
- Robert RadtkeChicago$7K
- Koree RamseyChicago$5K
- Justin OkrayChicago$5K
- Alexis DavidmanChicago$5K
- Brittany RankChicago$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.